Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer

Video

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

In the study, 196 patients were randomized to receive the veliparib combination regimen or placebo plus chemotherapy. Veliparib plus chemotherapy demonstrated improvements for both progression-free survival and overall survival compared with chemotherapy alone, which was carboplatin and paclitaxel, Diéras says. Additionally, the overall response rate with veliparib was found to be statistically significant.

Regarding safety, veliparib was associated with no meaningful adverse events, she adds. The most common treatment-emergent adverse events in either arm were neutropenia, thrombocytopenia, and nausea.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD